LMAT vs. ATEC, IART, MDXG, NVCR, ATRC, ICUI, CATX, AORT, NARI, and SILK
Should you be buying LeMaitre Vascular stock or one of its competitors? The main competitors of LeMaitre Vascular include Alphatec (ATEC), Integra LifeSciences (IART), MiMedx Group (MDXG), NovoCure (NVCR), AtriCure (ATRC), ICU Medical (ICUI), Perspective Therapeutics (CATX), Artivion (AORT), Inari Medical (NARI), and Silk Road Medical (SILK). These companies are all part of the "surgical & medical instruments" industry.
Alphatec (NASDAQ:ATEC) and LeMaitre Vascular (NASDAQ:LMAT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations.
LeMaitre Vascular has lower revenue, but higher earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.
Alphatec has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500.
In the previous week, Alphatec had 5 more articles in the media than LeMaitre Vascular. MarketBeat recorded 8 mentions for Alphatec and 3 mentions for LeMaitre Vascular. LeMaitre Vascular's average media sentiment score of 1.24 beat Alphatec's score of 1.05 indicating that Alphatec is being referred to more favorably in the media.
66.4% of Alphatec shares are owned by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are owned by institutional investors. 22.8% of Alphatec shares are owned by insiders. Comparatively, 10.8% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Alphatec presently has a consensus target price of $22.89, indicating a potential upside of 122.65%. LeMaitre Vascular has a consensus target price of $73.83, indicating a potential downside of 7.90%. Given LeMaitre Vascular's stronger consensus rating and higher probable upside, equities research analysts plainly believe Alphatec is more favorable than LeMaitre Vascular.
LeMaitre Vascular has a net margin of 16.99% compared to LeMaitre Vascular's net margin of -37.45%. Alphatec's return on equity of 11.57% beat LeMaitre Vascular's return on equity.
LeMaitre Vascular received 187 more outperform votes than Alphatec when rated by MarketBeat users. Likewise, 70.86% of users gave LeMaitre Vascular an outperform vote while only 56.68% of users gave Alphatec an outperform vote.
Summary
LeMaitre Vascular beats Alphatec on 10 of the 18 factors compared between the two stocks.
Get LeMaitre Vascular News Delivered to You Automatically
Sign up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LeMaitre Vascular Competitors List
Related Companies and Tools
